Effect of dabrafenib combined with trametinib on braf mutation

The combination of dabrafenib and trametinib has shown significant efficacy in the treatment of advanced or metastatic melanoma caused by BRAF V600 mutations. BRAF V600Mutation is one of the most common types of mutations in melanoma, accounting for about half of patients. These mutations lead to abnormal activation of cell signaling pathways and promote the development and spread of melanoma. Dabrafenib is a BRAF inhibitor that inhibits the activity of mutant BRAF proteins, thereby inhibiting the growth and spread of melanoma cells. Trametinib is a MEK inhibitor that can inhibit the MEK protein in the cell signaling pathway and further inhibit the proliferation of melanoma cells.